Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
Studying the efficacy of IL-6 inhibition utilizing single or double dose subcutaneous administration of Sarilumab in patients with severe respiratory distress caused by COVID19 regarding improvement in oxygen demands and other clinical outcomes.
Epistemonikos ID: a9cdce3f9d964b2bb801f313f4866cffe958c1c5
First added on: Sep 30, 2025